In 2012, important advances were made in understanding the pathogenesis of IBD—the Immunochip project increased the number of known IBD loci to 163, and underscored the common susceptibility to infectious diseases. With regard to management of IBD, novel non-anti-TNF agents have shown efficacy in phase II and III trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Jostins, L. et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
Louis, E. et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142, 63–70 (2012).
Laharie, D. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(12)61084-8.
Sandborn, W. J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616–624 (2012).
Sandborn, W. J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519–1528 (2012).
Rutgeerts, P. on behalf of the GEMINI I working group. Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial [abstract]. Gut 61 (Suppl. 3), A65 (2012).
Colombel, J. F. on behalf of the GEMINI II working group. Vedolizumab Maintenance Therapy for Crohn's Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial [abstract]. Gut 61 (Suppl. 3), A32 (2012).
Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).
O'Connor, W. Jr et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 10, 603–609 (2009).
Puel, A. et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65–68 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S. Vermeire and P. Rutgeerts receive grant support and speaker's honoraria from Abbott, MSD, Pfizer and UCB Pharma.
Supplementary information
Supplementary Table 1
Novel therapeutic approaches show variable efficacy in different immune-mediated diseases (DOC 43 kb)
Rights and permissions
About this article
Cite this article
Vermeire, S., Rutgeerts, P. Pathogenesis and management of IBD—thinking outside the box. Nat Rev Gastroenterol Hepatol 10, 67–69 (2013). https://doi.org/10.1038/nrgastro.2012.241
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2012.241